GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Comera Life Sciences Holdings Inc (OTCPK:CMRA) » Definitions » Piotroski F-Score

Comera Life Sciences Holdings (Comera Life Sciences Holdings) Piotroski F-Score : N/A (As of May. 24, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Comera Life Sciences Holdings Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Comera Life Sciences Holdings has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Comera Life Sciences Holdings's Piotroski F-Score or its related term are showing as below:


Comera Life Sciences Holdings Piotroski F-Score Historical Data

The historical data trend for Comera Life Sciences Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Comera Life Sciences Holdings Piotroski F-Score Chart

Comera Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22
Piotroski F-Score
N/A N/A N/A

Comera Life Sciences Holdings Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Comera Life Sciences Holdings's Piotroski F-Score

For the Biotechnology subindustry, Comera Life Sciences Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Comera Life Sciences Holdings's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Comera Life Sciences Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Comera Life Sciences Holdings's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Net Income was -2.963 + -2.481 + -1.412 + -2.154 = $-9.01 Mil.
Cash Flow from Operations was -1.848 + -1.906 + -0.994 + -1.914 = $-6.66 Mil.
Revenue was 0.156 + 0.393 + 0.315 + 0.136 = $1.00 Mil.
Gross Profit was 0.106 + 0.276 + 0.259 + 0.094 = $0.74 Mil.
Average Total Assets from the begining of this year (Sep22)
to the end of this year (Sep23) was
(4.937 + 3.727 + 2.999 + 2.34 + 3.072) / 5 = $3.415 Mil.
Total Assets at the begining of this year (Sep22) was $4.94 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $2.63 Mil.
Total Current Liabilities was $2.93 Mil.
Net Income was -2.024 + -2.879 + -9.085 + -3.077 = $-17.07 Mil.

Revenue was 0.073 + 0.095 + 0.147 + 0.235 = $0.55 Mil.
Gross Profit was 0.034 + 0.051 + 0.092 + 0.174 = $0.35 Mil.
Average Total Assets from the begining of last year (Sep21)
to the end of last year (Sep22) was
(0 + 7.418 + 0 + 6.131 + 4.937) / 5 = $6.162 Mil.
Total Assets at the begining of last year (Sep21) was $0.00 Mil.
Long-Term Debt & Capital Lease Obligation was $0.17 Mil.
Total Current Assets was $4.29 Mil.
Total Current Liabilities was $3.43 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Comera Life Sciences Holdings's current Net Income (TTM) was -9.01. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Comera Life Sciences Holdings's current Cash Flow from Operations (TTM) was -6.66. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep22)
=-9.01/4.937
=-1.82499494

ROA (Last Year)=Net Income/Total Assets (Sep21)
=-17.065/0
=

Comera Life Sciences Holdings's return on assets of this year was -1.82499494. Comera Life Sciences Holdings's return on assets of last year was . ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Comera Life Sciences Holdings's current Net Income (TTM) was -9.01. Comera Life Sciences Holdings's current Cash Flow from Operations (TTM) was -6.66. ==> -6.66 > -9.01 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=0/3.415
=0

Gearing (Last Year: Sep22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep21 to Sep22
=0.172/6.162
=0.02791302

Comera Life Sciences Holdings's gearing of this year was 0. Comera Life Sciences Holdings's gearing of last year was 0.02791302. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep23)=Total Current Assets/Total Current Liabilities
=2.63/2.932
=0.89699864

Current Ratio (Last Year: Sep22)=Total Current Assets/Total Current Liabilities
=4.289/3.43
=1.25043732

Comera Life Sciences Holdings's current ratio of this year was 0.89699864. Comera Life Sciences Holdings's current ratio of last year was 1.25043732. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Comera Life Sciences Holdings's number of shares in issue this year was 23.113. Comera Life Sciences Holdings's number of shares in issue last year was 16.024. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.735/1
=0.735

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.351/0.55
=0.63818182

Comera Life Sciences Holdings's gross margin of this year was 0.735. Comera Life Sciences Holdings's gross margin of last year was 0.63818182. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep22)
=1/4.937
=0.20255216

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep21)
=0.55/0
=

Comera Life Sciences Holdings's asset turnover of this year was 0.20255216. Comera Life Sciences Holdings's asset turnover of last year was . ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Comera Life Sciences Holdings has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Comera Life Sciences Holdings  (OTCPK:CMRA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Comera Life Sciences Holdings Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Comera Life Sciences Holdings's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Comera Life Sciences Holdings (Comera Life Sciences Holdings) Business Description

Traded in Other Exchanges
N/A
Address
12 Gill Street, Suite 4650, Woburn, MA, USA, 01801
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.
Executives
Michael Gerard Campbell officer: Chief Financial Officer C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Charles Cherington 10 percent owner ONE BOW STREET, CAMBRIDGE MA 02138
David Soane 10 percent owner C/O SOANE LABS, LLC, 380 NE 72ND TERRACE, MIAMI FL 33138
Robert Patrick Mahoney officer: Chief Scientific Officer 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Barbara K Finck director C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118
Kirsten Flowers director C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
James Sherblom director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Stuart A Randle director 585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Sullivan Edward Aloysius Jr. director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Sirshendu Roopom Banerjee director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Janice Mccourt officer: Chief Business Officer C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Jeffrey S. Hackman director, officer: See Remarks 12 GILL STREET, SUITE 4650, WOBURN MA 01801
John D. Yee director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Neal Muni officer: See Remarks 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Phoenix Venture Partners Lp 10 percent owner 36 DOCKSIDE CIRCLE, REDWOOD SHORES CA 94065